Ranbaxy Laboratories Limited is the largest pharmaceutical company of India. The company came into existence in the year 1961. Ranbaxy Laboratories Limited has a reputed global presence. Currently the pharma giant is exporting its products to 125 countries. It has ground operations set at 46 countries worldwide. Moreover, as of now they have manufacturing facilities in 7 countries. Ranbaxy Laboratories Limited went public in the year 1973. The headquarters are located at Gurgaon, Haryana, India. In the year 2008, Daiichi Sankyo earned majority control over the pharma company.
As per the official reports, for the quarter eneded on 30th June, 2009, consolidated net sales were $ 368 million (Rs. 17,953 million); a growth of 14% over the first quarter of 2009.
In some latest developments the company has restructured the executive leadership level. Ranbaxy Laboratories Limited has entered into an agreement wit Ochoa Laboratories Limited of India. This has given Ranbaxy an opportunity to acquire Ochoa brands in pain management and dermatology. In a different step the company has announced its plans for the commencement of Phase-III clinical trials for its anti-malaria combination drug in India, Thailand and Bangladesh. The drug is known as Arterolane Maleate with Piperaquine Phosphate.
Ranbaxy Laboratories Limited was founded by Gurbax Singh and Ranbir Singh in the year 1937. They started the company as a distributor of the Japanese company Shionogi. The name Ranbaxy was tagged by taking Ran of Ranbir and Bax of Gurbax. The company was sold several times among the family members. Finally in the year 2008 Daiichi Sankyo earned majority control over the pharma company.
As of now, Ranbaxy Laboratories Limited is a trusted company both in terms of product delivery and investment market. If you are planning to buy stocks in this pharma giant then you can request expert analysis or tips from this platform. Looking at its present market strength, it is better to invest money in this script keeping in view long term planning and as defensive stock in your portfolio.
Like Posts on this Website? Subscribe to tips on stock market Feed
Hold Ranbaxy with stop loss of Rs 455, says Kunal Saraogi, technical analyst, on Zee Business. It has good fundamentals, he adds. The stock is currently trading at Rs 462.85, up 0.3% on the BSE.
Hold Ranbaxy with target of Rs 560 on crossing its resistance of Rs 492 and keep stop loss of Rs 442, says Hitesh Chotalia, technical analyst, on NDTV Profit. The stock is currently trading at Rs 458, down 0.7% on the BSE.
Buy Ranbaxy with target of Rs 470 and stop loss of Rs 442, says Salil Sharma, technical analyst, on NDTV Profit. The stock is currently trading at Rs 455.50, up 1.3% on the BSE.
Buy Ranbaxy with target of Rs 449 and stop loss of Rs 427, says Salil Sharma, technical analyst, on NDTV Profit. The stock is currently trading at Rs 442, up 0.4% on the BSE.